
Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows. The three-year-long trial, funded by the drugs’ maker, Eli Lilly, also found “sustained weight loss through the treatment period, with adults on the… read on > read on >